Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
rivastigmine, Quantity: 27 mg
Arrotex Pharmaceuticals Pty Ltd
Rivastigmine
Drug delivery system, transdermal
Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica
Transdermal
7 sachets, 30 sachets
(S4) Prescription Only Medicine
RIVASTIGMINE GENPAR PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.
Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2017-01-25